Dr. Myla Lai-Goldman, MD
Chief Executive Officer

Dr. Lai-Goldman is the Chief Executive Officer and President of GeneCentric Therapeutics. She is also a founder and director of the Company. Dr. Lai-Goldman spent more than 18 years at Laboratory Corporation of America, Holdings (LabCorp), the last 10 years as Executive Vice President, Chief Medical Officer and Chief Scientific Officer. She served on LabCorp’s Executive and Management Committees, with strategic and operations responsibilities for 3 major genomic laboratories comprising more than 700 people. During her tenure at the Company, she led all clinical, scientific and medical activities, including the introduction of more than 400 clinical assays. Her experience includes the development of partnerships, licensing, and acquisitions. After leaving LabCorp, Dr. Lai-Goldman became a Venture Partner at Hatteras Venture Partners and is the managing partner of Personalized Science, LLC, a consulting company founded to assist customers achieve successful adoption of innovative diagnostics. Dr. Lai-Goldman received her BS from the University of Pensylvania and MD from Columbia University College of Physicians and Surgeons. Dr. Lai-Goldman is Board-certified in anatomic and clinical pathology.


pic2Walter M. Capone, MBA
Chief Business Officer

Mr. Walter Capone is Chief Business Officer of GeneCentric Therapeutics. He most recently served as CEO and President of the Multiple Myeloma Research Foundation (MMRF) and the Multiple Myeloma Research Consortium (MMRC), advancing industry, academic research, government agency and patient community collaborations to drive breakthroughs for patients. The launch of the landmark CoMMpassSM Study, support in advancing six new myeloma therapies to market, and expansion in innovative academic/industry partnerships were among his numerous accomplishments. Prior to the MMRF, Walter had over 20 years of pharmaceutical and biotechnology leadership experience in Commercial Development, Operations, Finance, Marketing and Sales in the United States and internationally at Progenics Pharmaceuticals, Trimeris Inc., Triangle Pharmaceuticals, Bristol-Myers Squibb, Wyeth, Cyanamid Benelux and Lederle. In that time, he managed commercial drug product portfolios valued at over $500M; led or co-led the development, US and International launches as well as commercialization of 18 novel drugs including Fuzeon®, Emtriva®, Tequin®, Zerit®, Videx®, Maxipime® and Zosyn®; and managed over 30 other individual drug brands. Walter received his MBA from Columbia University Business School and BA from Brown University.


picDr. Hawazin Faruki, DrPH
Chief Scientific Officer
Dr. Hawazin Faruki leads GeneCentric’s research and clinical development activities. She joined GeneCentric with over 20 years experience in managing the successful development of genomic-based diagnostics. As Vice President of Operations at the Center for Molecular Biology and Pathology, and subsequently as Vice President of Clinical Development at Laboratory Corporation of America, she guided the successful introduction of multiple molecular diagnostics in virology, pharmacogenetics, and oncology. Dr. Faruki has extensive knowledge of molecular diagnostic platforms, clinical study design, and drug/diagnostic applications. Her interest in personalized medicine lead to investigation of factors necessary for successful companion diagnostic introductions and barriers that delay test adoption; topics she has explored in several peer-reviewed publications. Dr. Faruki received her doctorate in Laboratory Practice from the University of North Carolina School of Public Health. She completed a fellowship in clinical microbiology at Washington University and a research fellowship in molecular pathology at the University of Pittsburgh.


To view the drug development team click here.

To view the scientific founders click here.

To view the board of directors click here